Merck Reports Top-line Data from the P-III (V503-064) Study of Gardasil 9 in Japanese Males
Shots:
- The P-III (V503-064) trial is to assess Gardasil 9 (V503) for preventing HPV-related anogenital persistent infection among males (n=1059, 16-26yrs.) across Japan, with 1EP to reduce the incidence of 6mos. anogenital persistent infection from HPV types 6/11/16/18 & 2EP to reduce infection from HPV types 31/33/45/52/58
- Study reached its 1 & 2EPs, depicting reduced the combined incidence of anogenital persistent infection from 9 HPV types with 3-dose regimen of Gardasil 9 vs PBO
- Merck will share the data with the regulatory authorities in Japan & other regions for the same plus will highlight at future conferences. Additionally, a confirmatory P-III study is underway to prevent HPV oral persistent infections
Ref: Merck | Image: Merck
Related News:- Merck Commences P-IIb/III (BRUNELLO) Clinical Evaluation of Restoret to Treat Diabetic Macular Edema (DME)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
